Annual Total Liabilities
$6.63 M
+$1.63 M+32.61%
31 December 2023
Summary:
GT Biopharma annual total liabilities is currently $6.63 million, with the most recent change of +$1.63 million (+32.61%) on 31 December 2023. During the last 3 years, it has fallen by -$28.46 million (-81.10%). GTBP annual total liabilities is now -86.90% below its all-time high of $50.62 million, reached on 31 December 2015.GTBP Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$4.66 M
+$903.00 K+24.02%
30 September 2024
Summary:
GT Biopharma quarterly total liabilities is currently $4.66 million, with the most recent change of +$903.00 thousand (+24.02%) on 30 September 2024. Over the past year, it has dropped by -$1.48 million (-24.11%). GTBP quarterly total liabilities is now -90.92% below its all-time high of $51.36 million, reached on 31 March 2015.GTBP Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTBP Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +32.6% | -24.1% |
| 3 y3 years | -81.1% | +18.9% |
| 5 y5 years | -52.7% | -75.2% |
GTBP Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -81.1% | +32.6% | -54.6% | +24.0% |
| 5 y | 5 years | -81.1% | +32.6% | -86.7% | +42.3% |
| alltime | all time | -86.9% | +6533.0% | -90.9% |
GT Biopharma Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.66 M(+24.0%) |
| June 2024 | - | $3.76 M(-18.3%) |
| Mar 2024 | - | $4.60 M(-30.6%) |
| Dec 2023 | $6.63 M(+32.6%) | $6.63 M(+8.0%) |
| Sept 2023 | - | $6.14 M(-3.7%) |
| June 2023 | - | $6.38 M(-9.3%) |
| Mar 2023 | - | $7.03 M(+40.6%) |
| Dec 2022 | $5.00 M(-51.2%) | $5.00 M(-2.2%) |
| Sept 2022 | - | $5.12 M(-41.4%) |
| June 2022 | - | $8.73 M(-9.5%) |
| Mar 2022 | - | $9.65 M(-5.9%) |
| Dec 2021 | $10.26 M(-70.8%) | $10.26 M(+161.6%) |
| Sept 2021 | - | $3.92 M(+19.7%) |
| June 2021 | - | $3.28 M(-9.7%) |
| Mar 2021 | - | $3.63 M(-89.7%) |
| Dec 2020 | $35.09 M(+78.1%) | $35.09 M(+14.3%) |
| Sept 2020 | - | $30.69 M(+7.5%) |
| June 2020 | - | $28.56 M(+35.0%) |
| Mar 2020 | - | $21.15 M(+7.3%) |
| Dec 2019 | $19.71 M(+40.5%) | $19.71 M(+5.0%) |
| Sept 2019 | - | $18.77 M(+12.2%) |
| June 2019 | - | $16.73 M(+7.8%) |
| Mar 2019 | - | $15.52 M(+10.6%) |
| Dec 2018 | $14.03 M(+423.7%) | $14.03 M(+6.1%) |
| Sept 2018 | - | $13.22 M(+47.7%) |
| June 2018 | - | $8.95 M(+76.4%) |
| Mar 2018 | - | $5.08 M(+89.5%) |
| Dec 2017 | $2.68 M(-85.9%) | $2.68 M(-4.4%) |
| Sept 2017 | - | $2.80 M(-86.1%) |
| June 2017 | - | $20.13 M(+9.7%) |
| Mar 2017 | - | $18.35 M(-3.2%) |
| Dec 2016 | $18.95 M(-62.6%) | $18.95 M(+9.1%) |
| Sept 2016 | - | $17.37 M(+7.2%) |
| June 2016 | - | $16.19 M(-20.1%) |
| Mar 2016 | - | $20.26 M(-60.0%) |
| Dec 2015 | $50.62 M(+66.2%) | $50.62 M(+105.8%) |
| Sept 2015 | - | $24.60 M(+6.8%) |
| June 2015 | - | $23.03 M(-55.2%) |
| Mar 2015 | - | $51.36 M(+68.6%) |
| Dec 2014 | $30.46 M(+370.0%) | $30.46 M(+162.3%) |
| Sept 2014 | - | $11.61 M(+65.5%) |
| June 2014 | - | $7.02 M(+3.1%) |
| Mar 2014 | - | $6.81 M(+5.0%) |
| Dec 2013 | $6.48 M(-1.2%) | $6.48 M(+7.5%) |
| Sept 2013 | - | $6.03 M(+4.7%) |
| June 2013 | - | $5.76 M(+6.5%) |
| Mar 2013 | - | $5.41 M(-17.6%) |
| Dec 2012 | $6.56 M(+25.5%) | $6.56 M(+3.7%) |
| Sept 2012 | - | $6.33 M(-3.6%) |
| June 2012 | - | $6.56 M(+20.8%) |
| Mar 2012 | - | $5.43 M(+3.8%) |
| Dec 2011 | $5.23 M(-7.5%) | $5.23 M(-0.9%) |
| Sept 2011 | - | $5.28 M(-9.0%) |
| June 2011 | - | $5.80 M(-19.0%) |
| Mar 2011 | - | $7.16 M(+26.7%) |
| Dec 2010 | $5.65 M(-20.5%) | $5.65 M(+1.1%) |
| Sept 2010 | - | $5.59 M(-9.5%) |
| June 2010 | - | $6.18 M(-23.1%) |
| Mar 2010 | - | $8.04 M(+13.1%) |
| Dec 2009 | $7.11 M(+66.5%) | $7.11 M(+37.3%) |
| Sept 2009 | - | $5.18 M(+4.3%) |
| June 2009 | - | $4.96 M(+9.7%) |
| Mar 2009 | - | $4.52 M(+5.9%) |
| Dec 2008 | $4.27 M(+32.3%) | $4.27 M(-3.1%) |
| Sept 2008 | - | $4.41 M(+6.0%) |
| June 2008 | - | $4.15 M(+2.0%) |
| Mar 2008 | - | $4.07 M(+26.2%) |
| Dec 2007 | $3.23 M(-58.6%) | $3.23 M(-21.8%) |
| Sept 2007 | - | $4.13 M(-3.6%) |
| June 2007 | - | $4.28 M(-17.0%) |
| Mar 2007 | - | $5.16 M(-33.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2006 | $7.80 M(+82.8%) | $7.80 M(+46.4%) |
| Sept 2006 | - | $5.33 M(+7.0%) |
| June 2006 | - | $4.98 M(+1.0%) |
| Mar 2006 | - | $4.93 M(+15.6%) |
| Dec 2005 | $4.27 M(+59.3%) | $4.27 M(+691.8%) |
| Sept 2005 | - | $539.00 K(-25.7%) |
| June 2005 | - | $725.00 K(-23.6%) |
| Mar 2005 | - | $949.00 K(-64.6%) |
| Dec 2004 | $2.68 M(+145.2%) | $2.68 M(-9.6%) |
| Sept 2004 | - | $2.96 M(-2.5%) |
| June 2004 | - | $3.04 M(+174.7%) |
| Mar 2004 | - | $1.11 M(+1.2%) |
| Dec 2003 | $1.09 M(+42.5%) | $1.09 M(+5.6%) |
| Sept 2003 | - | $1.03 M(-3.4%) |
| June 2003 | - | $1.07 M(+26.4%) |
| Mar 2003 | - | $847.00 K(+10.4%) |
| Dec 2002 | $767.00 K(-35.4%) | $767.00 K(+9.6%) |
| Sept 2002 | - | $700.00 K(-23.8%) |
| June 2002 | - | $919.00 K(-13.5%) |
| Mar 2002 | - | $1.06 M(-10.5%) |
| Dec 2001 | $1.19 M(-23.5%) | $1.19 M(+7.6%) |
| Sept 2001 | - | $1.10 M(-25.1%) |
| June 2001 | - | $1.47 M(+8.4%) |
| Mar 2001 | - | $1.36 M(-12.4%) |
| Dec 2000 | $1.55 M(-37.8%) | $1.55 M(-1.6%) |
| Sept 2000 | - | $1.58 M(-5.5%) |
| June 2000 | - | $1.67 M(-7.0%) |
| Mar 2000 | - | $1.80 M(-28.0%) |
| Dec 1999 | $2.50 M(-37.7%) | $2.50 M(+18.8%) |
| Sept 1999 | - | $2.10 M(0.0%) |
| June 1999 | - | $2.10 M(-4.5%) |
| Mar 1999 | - | $2.20 M(-45.1%) |
| Dec 1998 | $4.00 M(-31.0%) | $4.00 M(-4.7%) |
| Sept 1998 | - | $4.20 M(-4.5%) |
| June 1998 | - | $4.40 M(-21.4%) |
| Mar 1998 | - | $5.60 M(-3.4%) |
| Dec 1997 | $5.80 M(+65.7%) | $5.80 M(+75.8%) |
| Sept 1997 | - | $3.30 M(+13.8%) |
| June 1997 | - | $2.90 M(-34.1%) |
| Mar 1997 | - | $4.40 M(+25.7%) |
| Dec 1996 | $3.50 M(-37.5%) | $3.50 M(+20.7%) |
| Sept 1996 | - | $2.90 M(+26.1%) |
| June 1996 | - | $2.30 M(-61.7%) |
| Mar 1996 | - | $6.00 M(+7.1%) |
| Dec 1995 | $5.60 M(+24.4%) | $5.60 M(+33.3%) |
| Sept 1995 | - | $4.20 M(-4.5%) |
| June 1995 | - | $4.40 M(-6.4%) |
| Mar 1995 | - | $4.70 M(+4.4%) |
| Dec 1994 | $4.50 M(+1400.0%) | $4.50 M(0.0%) |
| Sept 1994 | - | $4.50 M(+246.2%) |
| June 1994 | - | $1.30 M(+160.0%) |
| Mar 1994 | - | $500.00 K(+66.7%) |
| Dec 1993 | $300.00 K(-50.0%) | $300.00 K(-50.0%) |
| Sept 1993 | - | $600.00 K(+200.0%) |
| June 1993 | - | $200.00 K(-66.7%) |
| Mar 1993 | - | $600.00 K(0.0%) |
| Dec 1992 | $600.00 K(+200.0%) | $600.00 K(+100.0%) |
| Sept 1992 | - | $300.00 K(+50.0%) |
| June 1992 | - | $200.00 K(>+9900.0%) |
| Mar 1992 | - | $0.00(-100.0%) |
| Dec 1991 | $200.00 K(0.0%) | $200.00 K(-66.7%) |
| Sept 1991 | - | $600.00 K(+200.0%) |
| Dec 1990 | $200.00 K(-60.0%) | $200.00 K(-60.0%) |
| Dec 1989 | $500.00 K(+66.7%) | $500.00 K(+66.7%) |
| Dec 1988 | $300.00 K(+50.0%) | $300.00 K(+50.0%) |
| Dec 1987 | $200.00 K(-60.0%) | $200.00 K(-60.0%) |
| Dec 1986 | $500.00 K(+400.0%) | $500.00 K(+400.0%) |
| Dec 1985 | $100.00 K(-66.7%) | $100.00 K(-66.7%) |
| Dec 1984 | $300.00 K(-62.5%) | - |
| Dec 1984 | - | $300.00 K |
| Feb 1984 | $800.00 K | - |
FAQ
- What is GT Biopharma annual total liabilities?
- What is the all time high annual total liabilities for GT Biopharma?
- What is GT Biopharma annual total liabilities year-on-year change?
- What is GT Biopharma quarterly total liabilities?
- What is the all time high quarterly total liabilities for GT Biopharma?
- What is GT Biopharma quarterly total liabilities year-on-year change?
What is GT Biopharma annual total liabilities?
The current annual total liabilities of GTBP is $6.63 M
What is the all time high annual total liabilities for GT Biopharma?
GT Biopharma all-time high annual total liabilities is $50.62 M
What is GT Biopharma annual total liabilities year-on-year change?
Over the past year, GTBP annual total liabilities has changed by +$1.63 M (+32.61%)
What is GT Biopharma quarterly total liabilities?
The current quarterly total liabilities of GTBP is $4.66 M
What is the all time high quarterly total liabilities for GT Biopharma?
GT Biopharma all-time high quarterly total liabilities is $51.36 M
What is GT Biopharma quarterly total liabilities year-on-year change?
Over the past year, GTBP quarterly total liabilities has changed by -$1.48 M (-24.11%)